Pyr-AI
| Clinical data | |
|---|---|
| Other names | 2-PYI; 2-Pyrrolidinylindane; 1-(2-Indanyl)pyrrolidine; Compound 10j |
| Drug class | Stimulant |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H17N |
| Molar mass | 187.286 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyr-AI, also known as 2-pyrrolidinylindane (2-PYI), is a stimulant drug of the 2-aminoindane family. It is the analogue of 2-aminoindane (2-AI) in which the amine has been replaced with a pyrrolidine group. The drug has been described as having strong and long-lasting amphetamine-like effects in rodents. Other 2-aminoindanes like 2-AI itself and NM-2-AI are known to act as potent monoamine releasing agents and reuptake inhibitors. Pyr-AI was first described in the scientific literature by 1973.